Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial
about
Interleukin-4-positive mast cells are highly associated with the extent of immediate allergic wheal reaction in the skin.Cytokine gene associations with self-report ratings of morning and evening fatigue in oncology patients and their family caregivers.STAT6 mediates interleukin-4 growth inhibition in human breast cancer cellsCurrent pharmacotherapy for the treatment of crescentic glomerulonephritis.Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92).Responsiveness of human neutrophils to interleukin-4: induction of cytoskeletal rearrangements, de novo protein synthesis and delay of apoptosis.IL-4 as a Repurposed Biological Drug for Myocardial Infarction through Augmentation of Reparative Cardiac Macrophages: Proof-of-Concept Data in Mice.A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer.Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors.Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats.Therapeutic exploitation of IPSE, a urogenital parasite-derived host modulatory protein, for chemotherapy-induced hemorrhagic cystitis.Protective effects of IL-4 on Bacillus Calmette-Guerin and lipopolysaccharide induced immunological liver injury in mice.
P2860
Q31891263-B628FC2B-5E1A-45CF-BBB0-E980E8047556Q33839327-F456C521-3C80-42E1-8DD8-F4C39D467DC9Q34929161-2535E8E8-C29B-4AAB-BC6D-51B2CBE9D1CBQ36623061-D31F0DC7-5E37-4B05-B024-E1459EFDBDFFQ36717432-78D0A760-8CA9-4A96-9630-A017CA58F17DQ36871195-E9C7A177-37E3-459D-8682-3E38BA6335B1Q38650726-7375C36C-D11E-4878-8BCA-083595749410Q40621897-9217A23A-25DE-4057-870C-BD61F9BC5989Q41431913-F3C9C9E2-E31E-4908-A694-83EFAA4EA02EQ45866590-C341C59B-2FC0-4BF5-85C2-CD79703F1FD8Q52610360-F8EA0E04-FD53-4FDB-8BB4-655473724CB5Q54346672-18FD56C2-83CF-4E26-943C-26B83CA79578
P2860
Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Recombinant human interleukin ...... -a phase I dose toxicity trial
@ast
Recombinant human interleukin ...... -a phase I dose toxicity trial
@en
type
label
Recombinant human interleukin ...... -a phase I dose toxicity trial
@ast
Recombinant human interleukin ...... -a phase I dose toxicity trial
@en
prefLabel
Recombinant human interleukin ...... -a phase I dose toxicity trial
@ast
Recombinant human interleukin ...... -a phase I dose toxicity trial
@en
P2093
P2860
P356
P1476
Recombinant human interleukin ...... -a phase I dose toxicity trial
@en
P2093
Gilleece MH
Heyworth CM
Scarffe JH
P2860
P2888
P304
P356
10.1038/BJC.1992.243
P407
P577
1992-07-01T00:00:00Z